Au­rinia gets two new as­sets in ac­qui­si­tion, li­cens­ing deal; Shorla preps T-cell leukemia drug for com­mer­cial­iza­tion

Au­rinia has ac­quired two new pipeline as­sets through a buy­out and re­search col­lab­o­ra­tion, the Cana­di­an biotech an­nounced Tues­day.

The first new com­pound comes from Thun­der­bolt Phar­ma, which Au­rinia ac­quired in an all-stock deal. Au­rinia’s new pro­gram is a re­com­bi­nant Fc fu­sion pro­tein de­signed to specif­i­cal­ly block B-cell Ac­ti­vat­ing Fac­tor, known as BAFF, and A Pro­lif­er­a­tion-In­duc­ing Lig­and, known as APRIL. The biotech hopes the pro­gram can treat au­toim­mune and nephrol­o­gy con­di­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER